Accession Number:

ADA621298

Title:

Platform for Rapid Delivery of Biologics and Drugs to Ocular Cells and Tissues Following Combat Associated Trauma

Descriptive Note:

Annual rept. 30 Aug 2013-29 Aug 2014

Corporate Author:

TUFTS UNIV BOSTON MA

Report Date:

2014-09-01

Pagination or Media Count:

16.0

Abstract:

The objective of this study is to develop a protein that can be injected directly into the eye while in the combat theater to prevent or reduce the damage to retinal cells following blast associated trauma. To this end, we propose use of a peptide POD, peptide for ocular delivery that we have previously shown to be capable of penetrating retinal cells in vivo. POD will be utilized to deliver melanoma inhibitor of apoptosis ML-IAP or X-linked inhibitor of apoptosis XIAP into retinal cells, neither of which have a cell penetrating capacity by themselves. We are using recombinant adenovirus as the gene expression system to synthesize the POD fusion proteins. At the end of Year 1 of this proposal, we have completed the construction of 1 XIAP of the recombinant adenovirus constructs and are at the penultimate step of generating the ML-IAP construct. Next steps are to purify these two proteins and evaluate their anti-apoptotic properties in vitro and ultimately in vivo. During the following year we will complete the construction of the ML-IAP construct and relevant controls and perform studies to test the anti-apoptotic properties of these recombinant proteins.

Subject Categories:

  • Biochemistry
  • Anatomy and Physiology
  • Medicine and Medical Research
  • Pharmacology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE